Sort
141,003 grants matching “cytokine”
Novel Strategies to Clear Bacteria from the CF Lung
$999,919Saira Ahmad · Eldec Pharmaceuticals, Inc. · R44 · FY2022 · HL
Novel IL-15 Superagonist Therapy for Bladder Cancer
$999,919Peter R Rhode · Altor Bioscience. Llc · R44 · FY2018 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer
$999,919John Lee · Altor Bioscience. Llc · R44 · FY2019 · CA
Improving Functioning in Peripheral Arterial Disease
$999,863Northwestern University · R01 · FY2003 · HL
Development of a protein drug for pancreatic cancer treatment
$999,780Zhi-Ren Liu · Proda Biotech, Llc · R42 · FY2018 · CA
Development of a protein drug for pancreatic cancer treatment
$999,780Zhi-Ren Liu · Proda Biotech, Llc · R42 · FY2019 · CA
Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity
$999,730Lisa Tussing-Humphreys · University Of Illinois At Chicago · R01 · FY2024 · CA
Immune Regulation in Mycobacterial and Fungal Infections
$999,676Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$999,615Timothy S McConnell · Isoplexis, Inc. · R44 · FY2020 · AG
An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants.
$999,601Martina Buck · Xfibra, Inc. · R44 · FY2024 · AI
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
$999,600Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2019 · CA
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2022 · CA
A treatment drug for triple negative breast cancer
$999,562Zhi-Ren Liu · Proda Biotech, Llc · U44 · FY2023 · CA
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome
$999,491Charles Andrew Stewart · Cartesian Therapeutics, Inc. · R44 · FY2022 · HL
Coordinate Regulation of Virulence in Vibrio Cholerae
$999,436John J Mekalanos · Harvard Medical School · R37 · FY2025 · AI
Coordinate Regulation of Virulence in Vibrio Cholerae
$999,436John J Mekalanos · Harvard Medical School · R37 · FY2024 · AI
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
$999,425Teodora Nicola · Alveolus Bio, Inc. · R44 · FY2024 · HL
Interleukin 4
$999,413William Paul · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Lymphocyte Dynamics
$999,413William Paul · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2022 · CA
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL
$999,336Manuel Litchman · Mustang Bio, Inc. · R44 · FY2021 · CA
Vaccine Development for Oral Carcinoma
$999,323University Of Pittsburgh At Pittsburgh · P01 · FY2005 · DE
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$999,300Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2022 · AI
PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments
$999,283Archis Bagati · Pyrojas Inc · R44 · FY2025 · CA
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma
$999,250Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2020 · CA